Home
> Product Overview
DEXDOMITOR
® (dexmedetomidine) is a purified α
2-agonist that is FDA-approved for the following:
- Sedation and analgesia in dogs and cats
- Proven safe and effective in dogs as young as 16 weeks
- Proven safe and effective in cats as young as 12 weeks
- Pre-anesthesia in dogs
- Approved for concurrent use with commonly used induction and anesthetic agents
- Reduces anesthetic requirements by 30-60%
Note: DEXDOMITOR has not been evaluated as a preanesthetic in cats.
DEXDOMITOR has other features that make it a particularly attractive option for clinical examinations and minor surgical or diagnostic procedures.
- Dosing flexibility
- Two dosing choices for sedation and analgesia in dogs:
- 375 mcg/m2 IV
- 500 mcg/m2 IM
- Two preanesthesia dosage choices in dogs:
- 125 mcg/m2 IM for cooperative sedation for an ambulatory patient
- 375 mcg/m2 IM for profound sedation
- Sedative and analgesic dose in cats: 40 mcg/kg IM
- Reversibility-of-sedation option with ANTISEDAN® (atipamezole)
- FDA-approved for use in dogs only
- An equal volume of ANTISEDAN administered IM reverses the effects of DEXDOMITOR within minutes
DEXDOMITOR contains only the active molecule as its proven predecessor DOMITOR, but in a purified formulation that possesses the same pharmacologic activity but delivers less total drug to be metabolized. DEXDOMITOR is given in the same dose volume as DOMITOR
NEXT: α2-agonists
Important Safety Information
Do not use DEXDOMITOR or DOMITOR in dogs and DEXDOMITOR in cats with cardiovascular disease, respiratory disorders, liver or kidney diseases, or in conditions of shock, severe debilitation, or stress due to extreme heat, cold or fatigue. As with all α2-adrenoceptor agonists, the potential for isolated cases of hypersensitivity, including paradoxical response (excitation), exists. Arrhythmias, bradycardia, emesis were observed in the DEXDOMITOR and DOMITOR clinical field studies in dogs. DEXDOMITOR has not been evaluated for use in breeding, pregnant, or lactating dogs and cats. In cats, vomiting, urinary incontinence and hypersalivation were observed with DEXDOMITOR. Occasional vomiting may occur with ANTISEDAN use. Rarely, brief state of excitement or apprehensiveness may be seen in treated dogs. Other potential side effects of α2-agonists include hypersalivation, diarrhea, and tremors. For additional safety information, refer to the Precautions, Adverse Reactions and Animal Safety sections of the full prescribing information of DEXDOMITOR, DOMITOR and ANTISEDAN.